این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
International Journal of Hematology-Oncology and Stem Cell Research، جلد ۱۸، شماره ۳، صفحات ۲۲۷-۲۳۹
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Comparison of Cyclophosphamide-Based Graft Versus Host Disease Prophylaxis after “Allogeneic Stem Cell Transplantation from 9/10 HLA Matched Unrelated Donor’’ with Standard Graft Versus Host Disease Prophylaxis after “10/10 HLA Matched Relative Donor’’ Tr
چکیده انگلیسی مقاله Background: Graft Versus Host Disease (GvHD), which can be observed at a rate of 30-80% after allogeneic stem cell transplantation (ASCT) is an important complication that adversely affects the survival and quality of the life of patients. Posttransplant cyclophosphamide (PTCy) effectively prevents GvHD after HLA-haploidentical ASCT. In our study, the use of PTCy in 1-antigen HLA-mismatched unrelated donor (9/10MMUD) ASCT was compared with standard GvHD prophylaxis in HLA-identical related donor (MRD) ASCT. Materials and Methods: We conducted a retrospective study of the comparison of 42 patients with 9/10 MMUD ASCT receiving PTCy+Methotrexate (MTX)+Calcineurin Inhibitor (CNI) and 37 patients with HLA-identical MRD who received MTX+CNI  in 3 bone marrow transplantation centers.  Results: Cumulative incidences of grade I-II (64.6% vs 45.4%, p=0.187) or grade III to IV acute GvHD (35.4% vs54.6%, p=0.187) and chronic GvHD (11.9% vs 29.7%, p=0.096) were similar in the PTCy group and control group. No statistically significant differences were observed between PTCy and the control group in overall survival rate (52.4% vs 62.2%, p=0.381), progression-free survival (1483.97 vs 1200.70 days, p=0.502), relapsed-related mortality rate (21.4% vs 16.2%, p=0.556) and treatment-related mortality rate (16.7% vs 21.6%, p=0.575). Conclusion: With the addition of PTCy to standard GvHD prophylaxis in 9/10MMUD ASCT, the risk of GvHD due to incompatibility and unrelated transplantation is eliminated, and transplantation success is achieved with MRD ASCT. PTCy-based prophylaxis is an effective and safe strategy to prevent GvHD in 9/10 MMUD ASCT without increasing the risk of relapse and treatment-related mortality.
کلیدواژه‌های انگلیسی مقاله
نویسندگان مقاله | Murat Yıldırım
Gülhane Educational and Research Hospital, Department of Hematology and Bone Barrow Transplantation Unit, Ankara, Turkiye


| Selim Sayın
Gülhane Educational and Research Hospital, Department of Hematology and Bone Barrow Transplantation Unit, Ankara, Turkiye


| Melda Cömert
Gülhane Educational and Research Hospital, Department of Hematology and Bone Barrow Transplantation Unit, Ankara, Turkiye


| Esra Şafak, Yılmaz
Gülhane Educational and Research Hospital, Department of Medical Informatics, Ankara, Turkiye


| Ferit Avcu
Ankara Memorial Hospital Department of Hematology and Bone Barrow Transplantation Unit, Ankara, Turkiye


| Ali Ural
Bayındır Sögütözü Hospital Department of Hematology and Bone Barrow Transplantation Unit, Ankara, Turkiye


| Meltem Aylı
Gülhane Educational and Research Hospital, Department of Hematology and Bone Barrow Transplantation Unit, Ankara, Turkiye
نشانی اینترنتی https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/2005
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات